GILEAD SCIENCES, INC. Deferred Revenue (Non-Current)
GILEAD SCIENCES, INC. (GILD) had Deferred Revenue (Non-Current) of $21.98 million as of 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2014-02-25
- 2013-12-31: Deferred Revenue, Noncurrent $21.98M.
- 2013-09-30: Deferred Revenue, Noncurrent $25.40M.
- 2013-06-30: Deferred Revenue, Noncurrent $28.77M.
- 2013-03-31: Deferred Revenue, Noncurrent $32.20M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2013-12-31 | $21.98M 10-K · filed 2014-02-25 |
| 2013-09-30 | $25.40M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $28.77M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $32.20M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $20.53M 10-K · filed 2014-02-25 |
| 2012-09-30 | $20.84M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $23.66M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $26.51M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $31.87M 10-K · filed 2013-02-27 |
| 2011-09-30 | $34.70M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $27.71M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $30.27M 10-Q · filed 2011-05-09 |
| 2010-12-31 | $32.84M 10-K · filed 2012-02-23 |
| 2010-09-30 | $39.45M 10-Q · filed 2010-11-08 |
| 2010-06-30 | $39.53M 10-Q · filed 2010-08-09 |
| 2010-03-31 | $41.49M 10-Q · filed 2010-05-10 |
| 2009-12-31 | $43.03M 10-K · filed 2011-02-28 |
| 2009-09-30 | $44.57M 10-Q · filed 2009-11-05 |
| 2009-06-30 | $53.42M 10-Q · filed 2009-08-05 |
| 2008-12-31 | $74.18M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |